Allegra-D generic
This article was originally published in The Tan Sheet
Executive Summary
Barr receives ANDA approval for the first generic version of Sanofi-Aventis' Allegra-D 12-hour tablets, (fexofenadine HCl/pseudoephedrine HCl extended release), FDA announces April 14. A launch would be "at risk" due to pending patent litigation with Sanofi-Aventis over both Allegra and Allegra-D formulations. Barr recently prevailed in a dispute with Impax, gaining 180-day exclusivity of generic Allegra-D. Sanofi-Aventis plans to launch a 24-hour formulation later this year...